Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $81,262.

  • Cumberland Pharmaceuticals' Share-based Compensation rose 6.40% to $81,262 in Q3 2025 from the same period last year, while for Sep 2025 it was $310,972, marking a year-over-year decrease of 3.12%. This contributed to the annual value of $301,895 for FY2024, which is 17.30% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Share-based Compensation stood at $81,262, which was up 0.71% from $80,686 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Share-based Compensation ranged from a high of $224,786 in Q4 2021 and a low of -$27,753 during Q2 2022.
  • For the 3-year period, Cumberland Pharmaceuticals' Share-based Compensation averaged around $82,100, with its median value being $80,686 (2025).
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Share-based Compensation plummeted by 114.46% in 2022 and then skyrocketed by 452.68% in 2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Share-based Compensation (MRQ) stood at $224,786 in 2021, then crashed by 43.54% to $126,905 in 2022, then decreased by 26.01% to $93,894 in 2023, then fell by 20.32% to $74,812 in 2024, then rose by 8.62% to $81,262 in 2025.
  • Its Share-based Compensation was $81,262 in Q3 2025, compared to $80,686 in Q2 2025 and $74,212 in Q1 2025.